<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573911</url>
  </required_header>
  <id_info>
    <org_study_id>07-002453</org_study_id>
    <secondary_id>IRUSESOM0546</secondary_id>
    <nct_id>NCT00573911</nct_id>
  </id_info>
  <brief_title>Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus</brief_title>
  <official_title>Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Barrett's Esophagus are known to have excessive distal esophageal acid exposure&#xD;
      comparable to patients with erosive esophagitis. A significant proportion of patients with BE&#xD;
      who are not symptomatic on treatment continue to have persistent acid reflux. High dose&#xD;
      esomeprazole is able to control acid reflux in patients with BE. The effect of acid reflux on&#xD;
      Barrett's esophagus stroma is currently unknown.&#xD;
&#xD;
      It is our hypothesis that stromal fibroblast activation in Barrett's esophagus is influenced&#xD;
      by acid reflux. The specific aim of this proposal will be: To assess the association between&#xD;
      acid reflux and subepithelial fibroblasts in Barrett's esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will conduct a prospective cohort study to assess the degree of stromal activation in&#xD;
      patients with LSBE (without dysplasia) who have adequate and inadequate control of acid&#xD;
      reflux in the distal esophagus. The study will be conducted in two phases.&#xD;
&#xD;
      Phase 1 (Pilot): 20 patients with LSBE without dysplasia will undergo endoscopy with biopsies&#xD;
      and a 24 hour pH study on treatment. Patients will then be divided into 2 groups:&#xD;
&#xD;
        -  Group A (GER): Those with ongoing acid reflux (characterized by either presence of&#xD;
           esophagitis [LA classification B,C or D1] on endoscopy, and/or a positive pH study on&#xD;
           treatment defined using standard criteria)&#xD;
&#xD;
        -  Group B (NGER): Those with controlled acid reflux (negative endoscopy and pH study on&#xD;
           treatment).&#xD;
&#xD;
      Stromal markers that will be assessed and compared between the 2 groups will include:&#xD;
      presence of activated myofibroblasts (detected by immunohistochemistry for vimentin and&#xD;
      smooth muscle actin).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Barrett's Esophagus</condition>
  <condition>GERD</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy and pH study</intervention_name>
    <description>endoscopy and PH study done one time</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior histological demonstration of Barrett's esophagus that is endoscopically&#xD;
             visible; length of visible segment &gt;/= 1 cms&#xD;
&#xD;
          -  Absence of dysplasia on prior biopsies&#xD;
&#xD;
          -  Laboratory studies:&#xD;
&#xD;
               -  Prothrombin time (INR) &lt; 1.5&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0 gm/dL&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 3 or 4&#xD;
&#xD;
          -  Inability to tolerate endoscopic procedures&#xD;
&#xD;
          -  Pregnancy: Females of child-bearing age will be screened with pregnancy test. Although&#xD;
             none of the procedures in the study are contraindicated in pregnancy, sedation used in&#xD;
             endoscopy can be contraindicated in early pregnancy&#xD;
&#xD;
          -  Prior esophageal surgery, or cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasad G Iyer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Prasad G. Iyer</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

